Dengue Haemorrhagic Fever and Dengue Shock Syndrome in the Context of the Integrated Management of Childhood Illness, World Health Organization, p.13, 2005. ,
Prospects for a dengue virus vaccine, Nature Reviews Microbiology, vol.193, issue.7, pp.518-528, 2007. ,
DOI : 10.1038/nrmicro1690
Molecular evolution of dengue viruses: Contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease, Infection, Genetics and Evolution, vol.9, issue.4, pp.523-563, 2009. ,
DOI : 10.1016/j.meegid.2009.02.003
Le virus de la dengue : cibles virales et antiviraux, Virologie, vol.11, issue.2, pp.121-133, 2007. ,
Dengue viral infections, Indian J Dermatol, vol.55, pp.68-78, 2010. ,
Models of dengue virus infection, Drug Discovery Today: Disease Models, vol.3, issue.1, pp.97-103, 2006. ,
DOI : 10.1016/j.ddmod.2006.03.014
Eco-bio-social determinants of dengue vector breeding: a multicountry study in urban and periurban Asia, Bulletin of the World Health Organization, vol.88, issue.3, pp.173-184, 2010. ,
DOI : 10.2471/BLT.09.067892
Surveillance du moustique exotique Aedes albopictus en France métropolitaine, ville d'Hyères (Var) http://www.villehyeres .fr/visiteur, 2010. ,
Dengue haemorrhagic fever: diagnosis, treatment, prevention and control : World Health Organization, 1997. ,
Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever, Tropical Medicine and International Health, vol.28, issue.8, pp.1238-55, 2006. ,
DOI : 10.1016/0035-9203(94)90225-9
Clinical Diagnosis and assessment of severity of confirmed dengue infections in Vietnamese Children: Is the World Health Organization Classification system helpful, Am J Trop Med Hyg, vol.70, issue.2, pp.172-181, 2004. ,
Assessment of World Health Organization definition of dengue hemorrhagic fever in North India, The Journal of Infection in Developing Countries, vol.4, issue.03, pp.150-155, 2010. ,
DOI : 10.3855/jidc.708
The WHO dengue classification and case definitions: time for a reassessment, The Lancet, vol.368, issue.9530, pp.368170-173, 2006. ,
DOI : 10.1016/S0140-6736(06)69006-5
Severe dengue: the need for new case definitions, The Lancet Infectious Diseases, vol.6, issue.5, pp.297-302, 2006. ,
DOI : 10.1016/S1473-3099(06)70465-0
Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever. Tropical Medicine and International Health, pp.111238-1255, 2006. ,
Dengue fever: new paradigms for a changing epidemiology, Emerging Themes in Epidemiology, vol.2, issue.1, p.1, 2005. ,
DOI : 10.1186/1742-7622-2-1
Etiology of interepidemic periods of mosquito-borne disease, Proceedings of the National Academy of Sciences, vol.97, issue.16, pp.979335-979344, 2000. ,
DOI : 10.1073/pnas.97.16.9335
Influence des changements climatiques globaux sur la progression des arboriroses, Ann. Méd. Vét, vol.150, pp.56-63, 2006. ,
Epidemiological Factors Associated with Dengue Shock Syndrome and Mortality in Hospitalized Dengue Patients in Ho Chi Minh City, Vietnam. Am, J. Trop. Med. Hyg, vol.84, issue.1, pp.127-134, 2001. ,
Dry Season Production of Filariasis and Dengue Vectors in American Samoa and Comparison with Wet Season Production, American Journal of Tropical Medicine and Hygiene, vol.81, issue.6 ,
DOI : 10.4269/ajtmh.2009.09-0115
Myanmar Dengue Outbreak Associated with Displacement of Serotypes 2, 3, and 4 by Dengue 1. Emerg Infect Dis, pp.593-600, 2004. ,
Multiyear Climate Variability and Dengue? El Nin?o Southern Oscillation, Weather, and Dengue Incidence in Puerto Rico, Mexico, and Thailand: A Longitudinal Data Analysis, PLoS Med, issue.11, pp.6-1000185, 2009. ,
Effects of the El Niñosouthern oscillation on dengue epidemics in Thailand, BMC Public Health, issue.9, p.422, 1996. ,
Challenges in predicting climate and environmental effects on vector-borne disease episystems in a changing world, Journal of Experimental Biology, vol.213, issue.6, pp.946-54, 2010. ,
DOI : 10.1242/jeb.037564
Turning points, reproduction number, and impact of climatological events for multi-wave dengue outbreaks, Tropical Medicine & International Health, vol.24, issue.6, pp.628-666, 2009. ,
DOI : 10.1111/j.1365-3156.2009.02277.x
Demographic and Clinical Features of Dengue Fever in Pakistan from 2003???2007: A Retrospective Cross-Sectional Study, PLoS ONE, vol.4, issue.9, 2010. ,
DOI : 10.1371/journal.pone.0012505.t002
Immunopathological mechanisms in dengue and dengue hemorrhagic fever, Current Opinion in Infectious Diseases, vol.19, issue.5, pp.429-436, 2006. ,
DOI : 10.1097/01.qco.0000244047.31135.fa
Neutralization and Antibody-Dependent Enhancement of Dengue Viruses, Adv Virus Res, vol.60, pp.421-67, 2003. ,
DOI : 10.1016/S0065-3527(03)60011-4
The relationship of interacting immunological components in dengue pathogenesis, Virology Journal, vol.6, issue.1, p.211, 2009. ,
DOI : 10.1186/1743-422X-6-211
Progress towards a dengue vaccine, The Lancet Infectious Diseases, vol.9, issue.11, pp.678-87 ,
DOI : 10.1016/S1473-3099(09)70254-3
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity, Cell Host Microbe, pp.271-83, 2010. ,
Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans, Science, pp.328745-328753, 2010. ,
Enhancement by Tumor Necrosis Factor Alpha of Dengue Virus-Induced Endothelial Cell Production of Reactive Nitrogen and Oxygen Species Is Key to Hemorrhage Development, J virol, issue.24, pp.8212312-12324, 2008. ,
Risk factors in dengue shock syndrome, Am J Trop Med Hyg, vol.56, issue.5, pp.566-572, 1997. ,
RISK FACTORS IN DENGUE SHOCK SYNDROME: A PROSPECTIVE EPIDEMIOLOGIC STUDY IN RAYONG, THAILAND, American Journal of Epidemiology, vol.120, issue.5, pp.653-669, 1984. ,
DOI : 10.1093/oxfordjournals.aje.a113932
Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks, Revista Panamericana de Salud P??blica, vol.11, issue.4, pp.223-230, 2002. ,
DOI : 10.1590/S1020-49892002000400003
Serotype-specific differences in clinical manifestations of dengue, Am J Trop Med Hyg, issue.3, pp.74449-56, 2006. ,
Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999, Am J Trop Med Hyg, issue.2, pp.68-191, 2003. ,
Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua, Am J Trop Med Hyg, vol.63, issue.1 2, pp.5-11, 2000. ,
Epidemiology of Inapparent and Symptomatic Acute Dengue Virus Infection: A Prospective Study of Primary School Children in Kamphaeng Phet, Thailand, American Journal of Epidemiology, vol.156, issue.1, pp.40-51, 2002. ,
DOI : 10.1093/aje/kwf005
A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996, Am J Trop Med Hyg, issue.3, pp.61-412, 1999. ,
Serotype-Specific Differences in the Risk of Dengue Hemorrhagic Fever: An Analysis of Data Collected in Bangkok, Thailand from 1994 to 2006, PLoS Neglected Tropical Diseases, vol.329, issue.1, p.617, 1994. ,
DOI : 10.1371/journal.pntd.0000617.t003
Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity, The Journal of Infectious Diseases, vol.181, issue.1, pp.2-9, 2000. ,
DOI : 10.1086/315215
Spatial and Temporal Circulation of Dengue Virus Serotypes: A Prospective Study of Primary School Children in Kamphaeng Phet, Thailand, American Journal of Epidemiology, vol.156, issue.1, pp.52-61, 2002. ,
DOI : 10.1093/aje/kwf006
Dengue Virus Evolution and Virulence Models, Clinical Infectious Diseases, vol.44, issue.11, pp.1462-1468, 2007. ,
DOI : 10.1086/517587
Dengue diagnostics: recommendations from the Asia-Pacific and the Americas dengue prevention boards. International Vaccine Institute ,
Etude comparative de deux tests de détection rapide de la protéine NS1 pour le diagnostic de la dengue, Thèse n°56, 2010. ,
A Small-Molecule Dengue Virus Entry Inhibitor, Antimicrobial Agents and Chemotherapy, vol.53, issue.5, pp.531823-1831, 2009. ,
DOI : 10.1128/AAC.01148-08
Antiviral Compounds Discovered by Virtual Screening of Small???Molecule Libraries against Dengue Virus E Protein, ACS Chemical Biology, vol.3, issue.12, pp.765-775, 2008. ,
DOI : 10.1021/cb800176t
Novel Dengue Virus-Specific NS2B/NS3 Protease Inhibitor, BP2109, Discovered by a High-Throughput Screening Assay, Antimicrobial Agents and Chemotherapy, vol.55, issue.1, pp.55229-238, 2011. ,
DOI : 10.1128/AAC.00855-10
Anthracene-based inhibitors of dengue virus NS2B???NS3 protease???, Antiviral Research, vol.89, issue.2, pp.127-162, 2011. ,
DOI : 10.1016/j.antiviral.2010.12.006
Structure-based discovery of dengue virus protease inhibitors, Antiviral Research, vol.82, issue.3, pp.110-114, 2009. ,
DOI : 10.1016/j.antiviral.2009.02.190
Inhibition of Dengue Virus Polymerase by Blocking of the RNA Tunnel, Journal of Virology, vol.84, issue.11, pp.845678-5686, 2010. ,
DOI : 10.1128/JVI.02451-09
Small Molecule Inhibitors That Selectively Block Dengue Virus Methyltransferase, Journal of Biological Chemistry, vol.286, issue.8, pp.2866233-2866273, 2010. ,
DOI : 10.1074/jbc.M110.179184
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057852
Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command, Am J Trop Med Hyg, issue.6, pp.691-695, 2003. ,
Safety and Immunogenicity of a Tetravalent Live-attenuated Dengue Vaccine in Flavivirus Naive Children, Am. J. Trop ,
Guidelines for the clinical evaluation of dengue vaccines in endemic areas, 2008. ,
Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses, p.7 ,
Dengue Plaque Reduction Neutralization Test (PRNT) in Primary and Secondary Dengue Virus Infections: How Alterations in Assay Conditions Impact Performance, American Journal of Tropical Medicine and Hygiene, vol.81, issue.5, pp.825-833, 2009. ,
DOI : 10.4269/ajtmh.2009.08-0625
Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys, Am, J. Trop. Med. Hyg, issue.6, pp.69-81, 2003. ,
Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii, Am. J. Trop ,
Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development, Infect Immun, issue.5, pp.141221-1227, 1976. ,
A, Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine, Am, J. Trop. Med. Hyg, issue.6, pp.69-117, 2003. ,
Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates, Am. J. Trop ,
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-na??ve adults, Human Vaccines, vol.5, issue.1, pp.33-40, 2009. ,
DOI : 10.4161/hv.5.1.6348
Efficacy of a live attenuated tetravalent candidate dengue vaccine in na??ve and previously infected cynomolgus macaques, Vaccine, vol.25, issue.29, pp.5409-5425, 2007. ,
DOI : 10.1016/j.vaccine.2007.04.079
A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness, Vaccine, vol.29, issue.22, pp.293895-904, 2011. ,
DOI : 10.1016/j.vaccine.2011.03.038
Live attenuated tetravalent dengue vaccine, Vaccine, vol.18, issue.2, pp.44-51, 2000. ,
DOI : 10.1016/S0264-410X(00)00040-2
Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers, Vaccine, vol.14, issue.4, pp.329-365, 1996. ,
DOI : 10.1016/0264-410X(95)00167-Y
Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers, Vaccine, vol.19, issue.23-24, pp.23-243179, 2001. ,
DOI : 10.1016/S0264-410X(01)00020-2
Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses, Am, J. Trop. Med. Hyg, issue.3, pp.66264-272, 2002. ,
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children, The Pediatric Infectious Disease Journal, vol.23, issue.2, pp.99-109, 2004. ,
DOI : 10.1097/01.inf.0000109289.55856.27
Immunogenicity and safety of two liveattenuated tetravalent dengue vaccine formulations in healthy Australian adults, Vaccine, issue.9, pp.241238-1241, 2006. ,
Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine, Vaccine, vol.19, issue.32, pp.194694-4699, 2001. ,
DOI : 10.1016/S0264-410X(01)00236-5
Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine, Am, J. Trop. Med. Hyg, issue.1, pp.7526-7554, 2006. ,
Développement d'un vaccin tétravalent contre la dengue, Virologie, vol.14, issue.5, pp.311-332, 2010. ,
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses, Vaccine, vol.28, issue.3, pp.28632-649, 2010. ,
DOI : 10.1016/j.vaccine.2009.09.098
Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine, Journal of Virology, vol.75, issue.16, pp.757290-7304, 2001. ,
DOI : 10.1128/JVI.75.16.7290-7304.2001
Attenuation and immunegeni-city of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys, Braz J Med Biol Res, issue.12, pp.381835-381881, 2005. ,
: a Yellow fever virus-based novel Japanese encephalitis vaccine, Expert Review of Vaccines, vol.9, issue.12, pp.1371-84, 2010. ,
DOI : 10.1586/erv.10.139
Dengue Type 4 Virus Mutants Containing Deletions in the 3' Non-coding Region of the RNA Genome: Analysis of Growth Restriction in Cell Culture and Altered Viremia Pattern and Immunogenicity in Rhesus Monkeys, J Virol, issue.6, pp.703930-3937, 1996. ,
Development of a Live Attenuated Dengue Virus Vaccine Using Reverse Genetics, Viral Immunology, vol.19, issue.1, pp.10-32, 2006. ,
DOI : 10.1089/vim.2006.19.10
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'- untranslated region, Am, J. Trop. Med. Hyg, issue.5, pp.65-405, 2001. ,
A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes, Am, J. Trop. Med. Hyg, issue.5, pp.65414-419, 2001. ,
A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys, Journal of Virology, vol.77, issue.2, pp.771653-1657, 2003. ,
DOI : 10.1128/JVI.77.2.1653-1657.2003
Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2, BMC Infectious Diseases, vol.77, issue.2, p.39, 2004. ,
DOI : 10.1128/JVI.77.7.3929-3938.2003
Genetically modified, live attenuated dengue virus type 3 vaccine candidates, Am. J ,
Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys, Vaccine, vol.21, issue.27-30, pp.27-304307, 2003. ,
DOI : 10.1016/S0264-410X(03)00488-2
rDEN4??30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers, The Journal of Infectious Diseases, vol.191, issue.5, pp.710-718, 2005. ,
DOI : 10.1086/427780
The Live Attenuated Dengue Serotype 1 ,
rDEN2/4??30(ME), a Live Attenuated Chimeric Dengue Serotype 2 Vaccine, is Safe and Highly Immunogenic in Healthy Dengue-Na??ve Adults, Human Vaccines, vol.2, issue.6, pp.255-260, 2006. ,
DOI : 10.4161/hv.2.6.3494
Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a Balanced, Broad, and Protective Neutralizing Antibody Response against Each of the Four Serotypes in Rhesus Monkeys, Journal of Virology, vol.79, issue.9, pp.795516-5528, 2005. ,
DOI : 10.1128/JVI.79.9.5516-5528.2005
Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3??? untranslated region (3???-UTR) or by exchange of the DENV-3 3???-UTR with that of DENV-4, Vaccine, vol.26, issue.6, pp.26817-828, 2008. ,
DOI : 10.1016/j.vaccine.2007.11.082
Phase I Clinical Evaluation of rDEN430- 200,201: A Live Attenuated Dengue 4 Vaccine Candidate Designed for Decreased Hepatotoxicity, Am J Trop Med Hyg, issue.5, pp.79678-684, 2008. ,
Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN430-4995 in healthy adult volunteers, Am J Trop Med Hyg, issue.5, pp.81834-841, 2009. ,
Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN430 with those of DEN1, Virol J, issue.4, p.23, 2007. ,
Third-Generation Flavivirus Vaccines Based on Single-Cycle, Encapsidation-Defective Viruses, Adv Virus Res, pp.77-126, 2008. ,
Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine, Journal of Virology, vol.74, issue.7, pp.743020-743028, 2000. ,
DOI : 10.1128/JVI.74.7.3020-3028.2000
Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys, Southeast Asian J Trop Med Public Health, vol.33, issue.3, pp.589-99, 2002. ,
Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development, Journal of Virology, vol.77, issue.21, pp.7711436-7711483, 2003. ,
DOI : 10.1128/JVI.77.21.11436-11447.2003
Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate, p.53 ,
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model, Vaccine, issue.35, pp.234442-4452, 2005. ,
Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice, Clinical and Vaccine Immunology, vol.17, issue.2, pp.304-306, 2010. ,
DOI : 10.1128/CVI.00353-09
Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys, Vaccine, vol.28, issue.15, pp.282705-2715, 2010. ,
DOI : 10.1016/j.vaccine.2010.01.022
A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity, Microbes and Infection, vol.11, issue.2, pp.288-295, 2009. ,
DOI : 10.1016/j.micinf.2008.12.004
Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice, International Immunology, vol.21, issue.10, pp.1175-1183, 2009. ,
DOI : 10.1093/intimm/dxp082
An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes, BMC Biotechnol, issue.10, p.7, 2007. ,
Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes, Clinical and Vaccine Immunology, vol.14, issue.2, pp.182-189, 2007. ,
DOI : 10.1128/CVI.00330-06
A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus, Journal of Virology, vol.82, issue.14, pp.826927-6934, 2008. ,
DOI : 10.1128/JVI.02724-07
Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus, PLoS Neglected Tropical Diseases, vol.61, issue.3, 2007. ,
DOI : 10.1371/journal.pntd.0000096.s002
URL : https://hal.archives-ouvertes.fr/pasteur-00285763
Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses, Vaccine, vol.28, issue.41, pp.286730-6739, 2010. ,
DOI : 10.1016/j.vaccine.2010.07.073
URL : https://hal.archives-ouvertes.fr/pasteur-00530065
Review of dengue virus and the development of a vaccine, Biotechnology Advances, vol.29, issue.2, pp.239-286, 2011. ,
DOI : 10.1016/j.biotechadv.2010.11.008
Induction of neutralization antibodies in mice by Dengue-2 envelope DNA vaccines, P R Health Sci J, issue.3, pp.28239-50, 2009. ,
Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys, Viral Immunol, vol.21, issue.2, pp.123-155, 2008. ,
A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection, Vaccine, vol.29, issue.4, pp.831-839, 2011. ,
DOI : 10.1016/j.vaccine.2010.10.078
Construction and Characterization of a Single-Cycle Chimeric Flavivirus Vaccine Candidate That Protects Mice against Lethal Challenge with Dengue Virus Type 2, Journal of Virology, vol.83, issue.4, pp.1870-1880, 2009. ,
DOI : 10.1128/JVI.01891-08
Efficient, trans-complementing packaging systems for chimeric, pseudoinfectious dengue 2/yellow fever viruses, Virology, vol.400, issue.1, pp.8-17, 2010. ,
DOI : 10.1016/j.virol.2009.12.015
Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy, Virology, vol.396, issue.2, pp.280-288, 2010. ,
DOI : 10.1016/j.virol.2009.10.023
Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas, Human Vaccines, vol.144, issue.10, pp.6802-809, 2010. ,
DOI : 10.1098/rstb.1999.0428